gory outcome variable was used, defined as the decision to 'recommend', 'restrict' or 'not recommend' a technology. Multivariate analyses were conducted to assess the relative contribution of the explanatory variables on coverage decisions both within and between HTA bodies. RESULTS: Different combinations of clinical/economic evidence, process and socio-economic factors drive HTA coverage decisions by NICE, SMC, CVZ and HAS. In addition, the same factor may behave differently according to the nature of the coverage decision. The analysis further suggests there is a significant difference between HTA bodies in the probability of reaching a 'restrict' or 'not recommend' decision outcome relative to a 'recommend' outcome, adjusted for evidence, process and context factors. CONCLUSIONS: This analysis contributes to the understanding of factors driving HTA coverage decisions by examining multiple European HTA bodies, enhancing the comprehensiveness of the factors examined through descriptive and multivariate analyses and by identifying and weighting the key drivers of the coverage decisions made by the four HTA bodies between 2004 and 2009. This research further provides relevant insights to variation among HTA bodies in the determination of patient access to pharmaceuticals, and implications for collaboration between European HTA bodies.
OBJECTIVES:
The Cancer Drugs Fund (CDF) was established in April 2011 by the UK government, with a pledge of £200 million additional funding for each of the next 3 years to increase patient access to high cost oncology drugs in England. As an interim measure, £50 million was distributed between the 10 strategic health authorities (SHAs) in England to cover the 6 months from October 2010 to March 2011. This research aims to identify how the interim CDF (ICDF) was spent, and to discuss how this could impact utilization of the CDF. METHODS: Data regarding the total funding allocated to each SHA from the ICDF and how much of this money had been spent by March 31, 2011 were obtained from SHA websites. Missing data were accessed through freedom of information requests. RESULTS: Overall, there were over 2700 applications to the fund, with an average approval rate of 91%. Over the 6 month period covered by the ICDF, approximately £21 million was spent across the 10 SHAs in England; this constituted 42% of the £50 million allocated. There was significant variation in the amount spent by each SHA; the highest under-spend was in the South West, where 75% of funds remained unallocated. Several SHAs reported the forecasted costs for continuing treatment beyond March 2011; these costs were incurred in the 2011/12 financial year and therefore were not covered by the ICDF. Remaining budget is expected to be reclaimed by the Department of Health. CONCLUSIONS: It is clear that there was a significant under-spend of the ICDF by all SHAs. It is concerning that many funding applications were rejected, despite the fact that almost half of the funds remained unallocated. Steps need to be taken to ensure more effective use of the CDF and to minimise the risk of regional variations in drug access.
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PMD1
ND-YAG LASER INCIDENCE RATE COMPARISON OF THREE MONOFOCAL INTRAOCULAR LENSES (IOL) 36 MONTHS AFTER CATARACT SURGERY IN FRANCE
Lafuma A 1 , Coulomb S 2 , Robert J 2 , Berdeaux G 3 1 CEMKA-EVAL, Bourg la Reine, France, 2 Cemka Eval, Bourg la Reine, France, 3 Alcon France, Rueil-Malmaison, France OBJECTIVES: The aim of this study was to compare the 36-month Nd-Yag laser (a treatment of posterior capsular opacification, the most frequent complication of cataract surgery) incidence rate of three monofocal IOLs: Acrysof SN60WF (Alcon), Akreos AO-MI-60 (Baush&Lomb) and Hoya YA-60BB (Hoya). METHODS: This is a retrospective study conducted at 3 French sites. Each centre implanted at least two of the above IOLs. Patients had to have uncomplicated cataract surgery with at least 2 years of follow-up. Patients implanted with one of the above IOLs were picked up at random from the surgery theatre registry. Medical data were retrieved from patient charts. 36-months post surgical data were obtained from the surgeon's medical files and from other ophthalmologists, if involved in post-surgical care. Time to Nd:Yag laser analysis was carried out using Kaplan-Meier survival curves. Confounding variable imbalances were adjusted with a stepwise Cox model. The statistical unit is the eye. RESULTS: 126 eyes were implanted with Acrysof, 89 with Akreos and 85 with Hoya. Patients with Acrysof were younger (72.1, 76.4 and 75.2 years; Pϭ0.0007). The sex ratio was 4 males: 6 females. Patient follow-up was longer in the Hoya eyes (27.8, 20 .3 and 32.1 months; Pϭ0.002). Eyes implanted with Acrysof had 1.68 times less Nd-Yag laser than Hoya (Pϭ0.06) and 3.43 times less than Akreos (PϽ0.0001). The results remained unchanged when the analysis was restricted to the events occurring during the first 36 months (HRϭ2.20; Pϭ0.009; HRϭ3.67; PϽ0.0001, respectively). Adjusting for confounding variable unbalances did not change the results. CONCLUSIONS: This analysis conducted at 36 months suggests that following usual surgical practice, Acrysof eyes had significantly less Nd-Yag laser capsulotomy than those implanted with Hoya and Akreos. Consequently, Acrysof eyes were less exposed to Nd-YAG laser complications and experienced lower post-surgical treatment costs.
PMD2 CLINICAL DECISION RULES FOR ADULTS WITH MINOR HEAD INJURY: A SYSTEMATIC REVIEW
Harnan SE, Pickering A, Pandor A, Goodacre SW The University of Sheffield, Sheffield, South Yorkshire, UK OBJECTIVES: A small number of cases of minor head injury deteriorate, resulting in serious injury or death. Computed Tomography (CT) identify intracranial injuries, but because it carries a cost and its own health risk, it should be limited to those most likely to have an injury. Clinical decision rules aim to identify these patients. There are many such rules, but it is unclear how their diagnostic accuracy compare. This study aimed to systematically identify clinical decision rules for adults with minor head injury and compare the estimated diagnostic accuracy. METHODS: Several key electronic bibliographic databases (biomedical, scientific and grey literature), were searched from inception to March 2010. Retrieved citations were considered for inclusion by at least two independent reviewers. Cohort studies that described a clinical decision rule to identify adults with minor head injury (GCS 13-15) at risk of intracranial injury or injury requiring neurosurgical intervention were included in the review. Data was extracted by one reviewer and checked by a second. Studies were quality assessed using the QuADAS tool. RESULTS: Twenty-two relevant studies were identified. No study satisfied all quality assessment items. Heterogeneity amongst patient selection criteria, outcome definitions, and reference standards was identified. The Canadian CT Head Rule (CCHR) high-risk criteria had sensitivity of 99-100% with specificity of 48-77% for injury requiring neurosurgical intervention. Other rules, such as New Orleans criteria, NEXUS II, NCWFNS and SIGN produce similar sensitivities but with lower and more variable specificity values. CONCLUSIONS: The most widely researched decision rule is the CCHR, which has consistently shown high sensitivity for identifying injury requiring neurosurgical intervention, with an acceptable specificity to allow considered use of cranial CT. No other decision rule has been validated as widely, or demonstrated similarly acceptable results. However, its exclusion criteria mean it may make it difficult to apply universally.
PMD3 BIOCHEMICAL MARKERS FOR THE IDENTIFICATION OF INTRACRANIAL INJURY FOLLOWING MINOR HEAD INJURY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Pickering A, Fitzgerald P, Harnan SE, Pandor A, Goodacre SW The University of Sheffield, Sheffield, South Yorkshire, UK OBJECTIVES: Minor head injury (MHI) can lead to deterioration, severe injury and death in a small number of cases. Using Computed Tomography (CT) scans on all those with MHI would result in large numbers receiving an unnecessary dose of radiation. Biochemical markers may be useful in reducing the number of scans. This study aimed to systematically identify and synthesize data estimating the diagnostic accuracy of biochemical markers for intracranial injury on CT in patients with MHI. METHODS: Key databases including MEDLINE, EMBASE & CINAHL were searched for potentially relevant literature. Studies reporting a cohort of more than 20 patients, with more than 50% having suffered a MHI (GCS 13-15), and which tested the diagnostic accuracy of a biochemical marker for intracranial or neurosurgical injury were included. Quality was assessed using the QUality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. Meta-analysis was used to estimate pooled sensitivity, specificity and likelihood ratios. RESULTS: Of the 12 included papers, nine provided diagnostic data on protein S100B only, one for Neuron-Specific Enolase (NSE) only, one for other markers and one study for both S100B and NSE levels. Data was only extracted and synthesized from S100B studies. Bayesian meta-analysis of these pooled data for 2442 adult subjects gave sensitivity of 96.8% (95% High Density Region (HDR), 93.8 to 98.6%) and specificity of 42.5% (95% HDR, 31.0 to 54.2%) with a negative likelihood ratio of 0.076 (95% HDR, 0.031 to 0.156). CONCLUSIONS: Evidence to support the addition of protein S100B as a triage tool for CT in MHI patients within three hours of injury is promising. Whilst the quality of studies is good, results are heterogeneous. S100B has the potential to be used in conjunction with a clinical decision rule. The marker therefore needs further testing as a component within such a diagnostic pathway. 
PMD4 EXPERT ELICITATION TO POPULATE EARLY HEALTH ECONOMIC MODELS OF MEDICAL DIAGNOSTIC DEVICES IN DEVELOPMENT
OBJECTIVES:
During the development of new diagnostic and therapeutic devices, it is desirable to indicate their cost-effectiveness and to establish their potential clinical value to guide further research. In these early stages of development, however, there are usually limited or no clinical data available. In this study, expert elicitation was used to estimate uncertain priors of the diagnostic performance of a new imaging technology, i.e. Photo Acoustic Mammography (PAM). We compared PAM to Magnetic Resonance Imaging (MRI), in the detection of breast cancer. METHODS: Expert elicitation was used as a method to formulate the knowledge and beliefs of experts about the future performance of PAM and to quantify this information into probability distributions. 18 radiologists estimated the true positive rate and true negative rate based on existing MRI data and specified the mode, the lower, and the upper boundaries (95% credible interval). An overall probability density function (PDF) was determined using the linear opinion pooling method in which weighting is applied to reflect the performance of individual experts. RESULTS: The overall PDF indicated a sensitivity ranging from 58.9% to 85.1%, with a mode of 73.3%. The specificity ranges from 52.2% to 77.6%, with a mode of 66.5%. Experts expressed difficulties making the estimations, as there is not sufficient A244 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
